Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing

K. De Leeneer, M. Van Bockstal, S. De Brouwer, N. Swietek, P. Schietecatte, N. Sabbaghian, J. Van den Ende, S. Willocx, K. Storm, B. Blaumeiser, C. J. Van Asperen, J. T. Wijnen, K. Leunen, E. Legius, G. Michils, G. Matthijs, M. J. Blok, E. Gomez-Garcia, A. De Paepe, M. TischkowitzB. Poppe, K. Claes

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)393-398
JournalBreast Cancer Research and Treatment
Volume133
Issue number1
DOIs
Publication statusPublished - May 2012

Keywords

  • Hereditary breast and ovarian cancer
  • RAD51C
  • Germline mutations
  • BRCA1/2-negative

Cite this

De Leeneer, K., Van Bockstal, M., De Brouwer, S., Swietek, N., Schietecatte, P., Sabbaghian, N., Van den Ende, J., Willocx, S., Storm, K., Blaumeiser, B., Van Asperen, C. J., Wijnen, J. T., Leunen, K., Legius, E., Michils, G., Matthijs, G., Blok, M. J., Gomez-Garcia, E., De Paepe, A., ... Claes, K. (2012). Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Research and Treatment, 133(1), 393-398. https://doi.org/10.1007/s10549-012-1998-4